Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760153 | 0.89 | PIK3CD (0.30) | PIK3CD | |
| SCHEMBL2736120 | 0.86 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3PIK3CD | |
| SCHEMBL2760066 | 0.81 | ALDH1A1 (0.32) | PIK3CD | |
| SCHEMBL18531991 | 0.77 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL2760149 | 0.75 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2736122 | 0.75 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL2760110 | 0.74 | PIK3CD (0.31) | PIK3CD | |
| SCHEMBL18531982 | 0.73 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL13780938 | 0.72 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL2736124 | 0.72 | ALDH1A1 (0.33) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20160303088-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160069915-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC, | 2016-03-10 | — | — | US | disclosed |
| US-20160067360-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20150225448-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150139948-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150011775-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-20140105859-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8383655-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8148374-B2 | Concurrent administering of drugs; side effect reduction | GILEAD SCIENCES, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8088770-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8067449-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110212964-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7939553-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090291952-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | PNP, UNG, PNPO | CHRNB2 4453/4885CHRNA4 4309/4885CHRNB4 4313/4885 |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | SLC10A1, SLC10A2, SLC26A4 | CHRNB2 3124/4885CHRNA4 3196/4885CHRNB4 2573/4885 |
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CHRNB2 3164/4885CHRNA4 3183/4885CHRNB4 2529/4885 |
| US-20140105859-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CHRNB2 3244/4885CHRNA4 4161/4885CHRNB4 3566/4885 |
| US-20160303088-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CHRNB2 3244/4885CHRNA4 4161/4885CHRNB4 3566/4885 |
| US-20150139948-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CHRNB2 3164/4885CHRNA4 3183/4885CHRNB4 2529/4885 |
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CHRNB2 3164/4885CHRNA4 3183/4885CHRNB4 2529/4885 |
| US-20150225448-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CHRNB2 3244/4885CHRNA4 4161/4885CHRNB4 3566/4885 |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CHRNB2 3244/4885CHRNA4 4161/4885CHRNB4 3566/4885 |
| US-20090291952-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CHRNB2 3244/4885CHRNA4 4161/4885CHRNB4 3566/4885 |
| US-20160067360-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CHRNB2 3244/4885CHRNA4 4161/4885CHRNB4 3566/4885 |
| US-20150011775-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CHRNB2 3244/4885CHRNA4 4161/4885CHRNB4 3566/4885 |
| US-20110212964-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CHRNB2 3244/4885CHRNA4 4161/4885CHRNB4 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.